News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
GlaxoSmithKline’s Pazopanib Shows Promise in Ovarian Cancer
September 15, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
LONDON, Sept 15 (Reuters) - GlaxoSmithKline's experimental drug pazopanib appears to be effective in fighting ovarian cancer, based on measurements of a biological marker used to predict tumour recurrence, researchers said on Monday.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase 2
Europe
GlaxoSmithKline
MORE ON THIS TOPIC
Sponsored
What Biopharma Can Learn from Formula 1: Precision, Speed, and the Power of the Right Partner
March 16, 2026
·
5 min read
Duchenne muscular dystrophy
Solid Adds to Differentiated Profile With New Data for Duchenne Gene Therapy
March 13, 2026
·
2 min read
·
Tristan Manalac
Rare diseases
BridgeBio Builds Case for Early 2027 Launch of Dystrophy Drug
March 12, 2026
·
2 min read
·
Tristan Manalac
Clinical research
MDA 2026: Biogen, Sarepta, Edgewise Address Muscle Disorders
March 12, 2026
·
3 min read
·
Tristan Manalac
